E-prescribing Safe and Efficient, Barriers Remain

WASHINGTON—Physician practices and pharmacies generally view electronic prescribing as an important tool to improve patient safety and save time, but both groups face barriers to realizing the technology’s full benefit, according to a study funded ...

New Data on Vimpat® (lacosamide) C-V to Be Presented at the 65th Annual Meeting of the American Epilepsy Society

ATLANTA, Nov. 30, 2011 /PRNewswire/ -- UCB, a leading biopharmaceutical company committed to the development of new epilepsy treatments and research, is proud to sponsor several key sets of Vimpat® (lacosamide) C-V data at the 65th Annual Meeting of the American...

Cytokinetics offers upbeat data from mid-stage trial of ALS drug

After failing to impress investors with previous data on its ALS drug, Cytokinetics' ($CYTK) stock price got a 4% bump this morning after the South San Francisco developer revealed data from a mid-stage trial involving patients with the incurable neurodegenerative disease. The company said that a part of the Phase II trial for the drug, dubbed CK-2017357, succeeded in "defining the tolerability and pharmacokinetic profile" during two weeks of therapy. The trial, involving 24 patients with...

FDA Establishes New Product Codes for Interbody Devices With Integrated Fixation

CLEVELAND, Nov. 30, 2011 /PRNewswire/ --RSB Spine announced today that it received a revised FDA clearance letter for the InterPlate® System as both an interbody implant with integrated fixation and an anterior screw fixation device.  FDA recently instituted new product...

The Sandwich Generation: More People Juggle Parenting and Caregiving Responsibilities

...

Affymetrix beefs up cancer research offerings in $330M eBioscience buyout

Affymetrix ($AFFY) took a big step forward in its pursuit of a larger swath of the market for cancer and immunology research products, announcing Wednesday that it has struck a deal to scoop up eBioscience for $330 million in cash. The pact comes after Santa Clara, CA-based Affymetrix, an early mover in the gene chip business, saw its revenues decline because of heavy competition in the gene expression microarray business, Xconomy reported. To build on Affymetrix's genomics business, the buyout...

Curis gets $4M for blood cancer therapy

The Leukemia & Lymphoma Society (LLS) has handed Lexington, MA-based Curis $4 million to support early development of two of the company's drugs for blood cancers. Curis' drug, CUDC-907, is an oral small molecule dual Pi3K and HDAC inhibitor for patients with B-cell lymphoma and multiple myeloma, the company said in a release. LLS said it would pay for half of the drug's development costs, up to $4 million, and in return will receive milestone payments from Curis if the developer...

Post Heart Attack Recovery Not Aided By Stem Cell Injections, But Trial Demonstrates Promise

  CLEVELAND, Nov. 30, 2011 /PRNewswire/ -- University Hospitals Case Medical Center researchers could still be close to giving heart attack patients a second chance…just not as they originally thought. The "LateTIME" trial was a study of adult stem cells...

Roche preps full data on blockbuster hopeful for breast cancer

After the FDA dropped its breast cancer label on Avastin this month, Swiss pharma giant Roche could regain some steam in early December when it presents full data on its late-stage experimental breast cancer drug pertuzumab. There's a lot riding on the success of the drug, which analysts have estimated could bring in about $2 billion in annual revenue if approved. At the annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS), which starts Dec. 6, the company will highlight full data...

NHS Direct decision aids – advanced kidney disease

...